Presentations from the Annual Small Cell Lung Cancer (SCLC) Research Consortium Meeting and the Consortium’s Virtual Meetings are posted as a reference.
2024
Annual Meeting
Small Cell Lung Cancer Consortium Meeting
May 1-2, 2024
NCI Shady Grove Campus, Rockville, MD
Virtual Meetings
“Interrogating the dynamics of tumor cell transdifferentiation via an organoid lineage exploration model”
Rodrigo Romero, PhD
Postdoctoral Research Fellow, Charles Sawyers Laboratory
Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center
“Olfactory neuroblastoma smells like small cell: mouse models uncover pan-neuroendocrine mechanisms”
Trudy Oliver, PhD
Professor of Pharmacology and Cancer Biology
Duke Cancer Institute, Duke University School of Medicine
“Targeting ABL-dependent replication-coupled DNA repair pathways in metastatic SCLC”
Ann Marie Pendergast, PhD
Anthony R. Means Cancer Biology Professor
Vice Chair, Department of Pharmacology and Cancer Biology
Director of Graduate Studies, Molecular Cancer Biology
Duke University School of Medicine
“Hepacam2 a novel and specific marker of Small Cell Carcinoma” and “Targets of antibody drug conjugates in Small Cell Lung Cancer”
Afshin Dowlati, MD
Professor of Medicine and Oncology
Case Western Reserve University
Rosalie and Morton Cohen Chair in Lung Cancer
Lucile and Robert Gries Endowed Director Center for Cancer Drug Development
Distinguished Physician
University Hospitals Seidman Cancer Center
Associate Director for Clinical Research, Case Comprehensive Cancer Center
“Autoantibody-antigen complexes identify targetable neoepitopes in small cell lung cancer”
Kristy Lastwika, PhD
Assistant Professor
Translational Science and Therapeutics Division
Fred Hutch Cancer Center
“Molecular and pathologic reclassification of SCLC-Y cell lines” and “Investigating the Role of γδ T cells in SCLC”
Jin Ng, PhD
Research Officer, Sutherland Lab
Walter and Eliza Hall Institute of Medical Research
“Targeting telomerase in SCLC”
Esra Akbay, PhD
Assistant Professor, Department of Pathology
The University of Texas Southwestern Medical Center
2023
IASLC 2023 Small Cell Lung Cancer Meeting
April 5–7, 2023
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Virtual Meetings
“Retinoblastoma Status in SCLC: response to chemotherapy, immunotherapy and CDK4/6 inhibitors”
Afshin Dowlati, MD
Professor of Medicine and Oncology | Case Western Reserve University
Rosalie and Morton Cohen Chair in Lung Cancer
Lucille and Robert Gries Endowed Director, Center for Cancer Drug Development
Director Phase I & Thoracic Oncology Programs, University Hospitals Seidman Cancer Center
Chief Academic Officer, Seidman Cancer Center
“SCLC-P”
Chris Vakoc, MD PhD
Professor, CSHL Cancer Center
Cold Spring Harbor Laboratory
“Dissecting SCLC heterogeneity: a patient-centered approach”
Anish Thomas, MBBS, MD
Lasker Clinical Research Scholar
Developmental Therapeutics Branch, Center for Cancer Research
National Cancer Institute
“NFIB-independent metastasis of small cell lung cancer”
Julie Ko
Graduate Student, Julien Sage Laboratory
Stanford University School of Medicine
“Uncovering the mechanism of HDAC3 loss mediated radiosensitivity in small-cell lung cancer”
Ujas A. Patel
Institute of Medical Sciences, University of Toronto
Lok Lab, Princess Margaret Cancer Research Tower, UHN
“Neuronal-Activity Dependent Mechanisms of Small Cell Lung Cancer Progression”
Husma Venkatesh, PhD
Assistant Professor, Neurology, Harvard Medical School
Associate Scientist, Neurology, Brigham And Women’s Hospital
Dana-Farber/Harvard Cancer Center
“Determinants of immune response in SCLC”
Charlie Rudin, MD, PhD
Chief, Thoracic Oncology Service
Sylvia Hassenfeld Chair in Lung Cancer Research
Co-Director, Druckenmiller Lung Center
Professor of Medicine, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
“Next-generation mouse models for SCLC ”
Julien Sage, PhD
Stanford University School of Medicine
Matt Oser, MD PhD
Dana-Farber Cancer Institute
Kwon Park, PhD
University of Virginia School of Medicine
“The Changing Ways of Small Cell Lung Cancer”
Mohamed Abazeed, MD, PhD
Associate Professor, Department of Radiation Oncology
Co-leader, Lung Cancer Program
Director, Center for Precision Radiotherapy
The Robert H. Lurie Comprehensive Cancer Center
Northwestern Memorial Hospital
“CDC7 inhibition prevents neuroendocrine transformation in lung and prostate tumors through MYC downregulation”
Álvaro Quintanal-Villalonga, PhD
Assistant Attending Biologist, Lab co-director
Department of Medicine
Memorial Sloan Kettering Cancer Center
“Extrachromosomal DNA Amplification of MYC paralogs Drive Cross-resistance in Small Cell Lung Cancer”
Benjamin J. Drapkin, MD, PhD
Assistant Professor, Hematology-Oncology
Hamon Center for Therapeutic Oncology Research
UT Southwestern Medical Center
“Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation”
Chia-Chun ’Olga’ Chen
PhD Candidate in Pharmacology, Graeber & Witte Laboratories
Department of Molecular and Medical Pharmacology
University of California, Los Angeles
“YAP1 defines a subtype of pulmonary LCNEC and an emergent, persister-cell population of relapsed SCLC.”
Carl Gay, MD, PhD
Assistant Professor, Department of Thoracic-Head & Neck Med Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Allison Stewart, PhD
Principal Research Scientist, Department of Thoracic-Head & Neck Med Oncology
The University of Texas MD Anderson Cancer Center
2022
Virtual Meetings
“Preclinical development of a DLL3-targeted theranostic for small cell lung cancer”
J.T. Poirier, PhD
Director, Preclinical Therapeutics Program
Assistant Professor, Department of Medicine
Perlmutter Cancer Center
NYU Langone Health
“Integrative analysis of a large real-world SCLC cohort reveals genetic subgroups, site-specific mutational patterns, and insights into histological transformation”
Christine Lovly, MD, PhD
Associate Professor of Medicine (Hematology/Oncology)
Ingram Associate Professor of Cancer Research
Co-Leader, Translational Research and Interventional Oncology Research Program
Vanderbilt University Medical Center
Smruthy Sivakumar, PhD
Senior Scientist, Cancer Genomics Research
Foundation Medicine
“Dissecting the plasticity of small cell lung cancer”
Martin Sos, MD
Molecular Pathology, Inst. for Pathology & Dept. for Translational Genomics,
Faculty of Medicine
University Hospital Cologne
Triparna Sen, PhD
Assistant Attending, Thoracic Oncology Service, Department of Medicine
Co-Director, Rudin & Sen Laboratory
Memorial Sloan Kettering Cancer Center
“A human pluripotent stem cell-based small cell lung cancer model with multiple-organ metastasis”
Joyce Chen, PharmD, PhD
Assistant Professor, Pritzker School of Molecular Engineering
The Ben May Department for Cancer Research
The University of Chicago
“Translating Autoantibody Biomarkers in Small Cell Lung Cancer”
Kristy Lastwika, PhD
Associate in Clinical Research
Fred Hutchinson Cancer Research Center
“Evaluating the roles of EMT and tumor genotypes in the tumorigenesis and chemoradiation response of small cell lung cancer.”
Triet Nguyen
Graduate Student, Phuoc Tran Laboratory
University of Maryland & Johns Hopkins University
“Targeting KDM4A, a histone lysine demethylase, in Small Cell Lung Cancer”
Aiden Nguyen
Graduate Student, John Minna & Elisabeth Martinez Laboratories
UT Southwestern Medical Center
“A multiplexed in vivo approach to identify driver genes in small cell lung cancer”
Myung Chang Lee (Noah Lee)
Graduate Student, Julien Sage Laboratory
Depts. of Pediatrics and Genetics
Stanford University School of Medicine
“Characterization of the role of ATOH1 in Small Cell Lung Cancer”
Alessia Catozzi
Graduate Student, Caroline Dive Laboratory
Cancer Research UK Manchester Institute (CRUK)
“Cell-free Tumor Methylome Analysis of Small Cell Lung Cancer Patients Identifies Subgroups with Prognostic Associations”
Sami Ul Haq, MSc
Research Assistant, Lok Laboratory
Princess Margaret Cancer Centre, University of Toronto
“Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small Cell Lung Cancer”
Benjamin Lok, MD FRCPC
Clinician-Scientist, Princess Margaret Cancer Centre
Assistant Professor, Department of Radiation Oncology, Institute of Medical Science, and Medical Biophysics, University of Toronto
“Introduction to SCLC Archetypes”
Vito Quaranta, MD
Professor, Biochemistry & Pharmacology
Director, Quantitative Systems Biology Center
Vanderbilt University Medical Center
“SCLC Subtype Transitions in Continuum Archetype Space”
Sarah Maddox Groves
PhD Candidate, Chemical & Physical Biology Program
Vanderbilt University Medical Center
“Model Inference of Regulatory Networks”
Bryan Glazer
PhD Candidate, Department of Biomedical Informatics
Vanderbilt University Medical Center
“Dynamics of lineage composition in SCLC tumors”
Samantha Beik
MD/PhD Candidate, Cancer Biology Graduate Program
Vanderbilt University Medical Center
“Wnt5a-Rhoa axis is a new vulnerability in small-cell lung cancer”
Kwon Park, PhD
Associate Professor, Microbiology, Immunology, and Cancer Biology
University of Virginia School of Medicine
“SCLC Research in Numbers”
Peter Ujhazy, MD, PhD
Deputy Associate Director, Translational Research Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Mehvish Khan, MS
Program Coordinator, Translational Research Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
“Targeting LSD1 to augment immune responses in SCLC”
David MacPherson, PhD
Professor, Human Biology Division;
Professor, Public Health Sciences Division
Fred Hutchinson Cancer Research Center
“Vesicular DLL3 mRNA and protein as SCLC biomarker”
L. James Lee, PhD
Helen C. Kurtz Chair Emeritus
Chemical and Biomolecular Engineering Faculty Emeritus
Department of Chemical and Biomolecular Engineering
The Ohio State University
“A plasma miRNA-based biomarker classifier for small cell lung cancer diagnosis”
Michela Saviana, PhD
Translational Lung Cancer Research Group (TLCaRG)
Division of Pulmonary Disease and Critical Care Medicine
Department of Internal Medicine
Virginia Commonwealth University
“Oncogenic Driver Intolerance Creates the Bottleneck to Histologic Transformation in Lung Cancer”
Eric Gardner, PharmD, PhD
Damon Runyon Fellow, Varmus Laboratory
Meyer Cancer Center, Weill Cornell Medicine
“Effective armored CAR T cell therapy against small cell lung cancer”
Janneke Jaspers, PhD
Senior Research Scientist
Memorial Hospital Laboratories, Charles Rudin Lab
Memorial Sloan Kettering Cancer Center
“Cancer Testis Antigens (CTAs) as a driver of chemoresistance in SCLC”
Michael S. Kareta, PhD
Associate Scientist, Genetics and Genomics Group
Cancer Biology and Immunotherapies Group
Sanford Research
Associate Scientist, Department of Pediatrics
University of South Dakota
“Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer”
Hua Zhang, MD, PhD
Assistant Professor of Medicine, Division of Hematology/Oncology
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center Research Pavilion
“cfDNA methylome profiling for detection and subtyping of Small Cell Lung Cancers”
Simon Pearce, PhD
Principal Mathematical Biologist
Cancer Biomarker Centre
Cancer Research UK Manchester Institute, University of Manchester
“Igf control of neuroendocrine stem cell activity in lung repair and SCLC initiation”
Mark Krasnow, MD, PhD
Paul and Mildred Berg Professor
Department of Biochemistry, Stanford University
Investigator, Howard Hughes Medical Institute
Helen Yue Zhang
Paul and Mildred Berg Graduate Fellow
Departments of Biology and Biochemistry, Stanford University
2021
Annual Meeting
IASLC 2021 Small Cell Lung Cancer Meeting
October 29-30, 2021
Virtual Conference
Program Agenda
Virtual Meetings
“Measuring collaboration trends within the NCI Small Cell Lung Cancer Consortium Using Coauthorships”
Melissa Antman, PhD
Senior Scientific Program Analyst
Christine Burgess, PhD
Health Scientist Administrator
Center for Research Strategy, National Cancer Institute
“Inhibition of Karyopherin B-1 mediated nuclear import of lineage-defining transcription factors in small cell lung cancer”
Demetra Kelenis
Graduate Student, Johnson Laboratory
UT Southwestern Medical Center
“Comparative genomic analyses of high-grade neuroendocrine malignancies of gynecological origin with SCLC”
Ata Abbas, PhD
Research Scientist, Department of Medicine
Member, Developmental Therapeutics Program
Case Comprehensive Cancer Center, CWRU
“NEUROD1 predicts sensitivity to BET bromodomain inhibitor in SCLC”
Haobin Chen, MD, PhD
Physician-Scientist Early Investigator, Thoracic Surgery Branch
Center for Cancer Research, National Cancer Institute
“Profiling SCLC chemoresistance on complementary single cell platforms”
Charlie Rudin, MD, PhD
Chief, Thoracic Oncology Service
Director, Druckenmiller Center for Lung Cancer Research
Memorial Sloan Kettering Cancer Center
“CRISPR/Cas9 screens to identify protein destabilizers of ASCL1”
Matthew Oser, MD, PhD
Instructor in Medicine, Harvard Medical School
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
“Characterizing chemo-radiation resistance in SCLC”
Christine Hann, MD, PhD
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Phuoc Tran, MD, PhD
Professor, Radiation Oncology and Molecular Radiation Sciences
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Luigi Marchionni, MD, PhD
Associate Professor of Pathology and Laboratory Medicine, Weill Cornell Medical School
“Deciphering metabolic vulnerabilities in small cell lung cancer”
Trudy Oliver, PhD
Associate Professor, Department of Oncological Sciences
Huntsman Cancer Institute, University of Utah
“Profiling mutations and transcription factor activity in SCLC patients using circulating cell-free DNA”
Joseph Hiatt, MD, PhD
Acting Instructor/Fellow, MacPherson Lab
Seattle Cancer Care Alliance
Fred Hutchinson Cancer Research Center
“CRISPR screening to identify new therapeutic vulnerabilities in SCLC”
David MacPherson, PhD
Associate Professor
Fred Hutchinson Cancer Research Center
“Tumor heterogeneity and immune environment in SCLC mouse models”
Carl Gay, MD PhD
Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Sarah Maddox Groves
PhD Candidate, Quaranta Laboratory
Chemical & Physical Biology Program
“Interrogating the role of Dll3 in histologic transformation of lung cancer”
Eric Gardner, PharmD, PhD
Postdoctoral Associate in Medicine, Varmus Laboratory
Myer Cancer Center, Weill Cornell Medicine
“Towards changing the course of a recalcitrant cancer by learning from every patient: Germline susceptibility to SCLC”
Anish Thomas, MBBS, MD
Lasker Clinical Research Scholar
Developmental Therapeutics Branch, Center for Cancer Research
National Cancer Institute
“Targeting small cell lung cancer with the first-in-class ubiquitin-activating enzyme (UAE/UBA1) inhibitor, TAK-243”
Benjamin Lok, MD, FRCPC
Clinician-Scientist, Princess Margaret Cancer Centre
Assistant Professor of Radiation Oncology, University of Toronto
“SCLC subtype-specific biomarker”
Simon Heeke, PhD
Postdoctoral Fellow, Heymach Laboratory
The University of Texas MD Anderson Cancer Center
“Differential ferroptotic responses in subtypes of small cell lung cancer”
Sylvia von Karstedt, PhD
Professor, Department of Translational Genomics, CECAD Research Center
Faculty of Medicine, University of Cologne, Germany
”CRISPR screen identifies a highly effective combination treatment for SCLC”
Alvaro Quintanal-Villalonga, PhD
Research Associate, Rudin/Sen Laboratory
Memorial Sloan Kettering Cancer Center
“EpicMIBI: A new approach to investigate intra-tumoral heterogeneity in SCLC”
Alexandros P. Drainas, PhD
Postdoctoral Fellow, Sage Laboratory
Stanford University
“Unique role and vulnerability of EP300 KIX in small-cell lung cancer”
Kwon Park, PhD
Associate Professor, Microbiology, Immunology & Cancer Biology
University of Virginia School of Medicine
“A two-step murine model of SCLC tumorigenesis”
Kate Sutherland PhD
Laboratory Head, Cancer Biology and Stem Cells Division
Associate Professor, Department of Medical Biology, University of Melbourne
Walter and Eliza Hall Institute of Medical Research
“Understanding neuroendocrine plasticity at the single-cell level in lung and prostate cancer”
Joe Chan, MD PhD
Instructor, Thoracic Oncology Service
Dana Pe’er & Charlie Rudin Laboratories
Memorial Sloan Kettering Cancer Center
“An essential POU2F3/OCT11 cofactor in normal tuft cells and SCLC-P tumors”
Xiaoli Wu
Graduate Student, Vakoc Laboratory
Cold Springs Harbor Laboratory
“Targeting glutamate signaling in small cell lung cancer”
Filippo Beleggia, MD, PhD
Junior Group Leader
Translational Genomics
Mildred Scheel School of Oncology
University Hospital of Cologne
2020
Annual Meeting
Small Cell Lung Cancer Consortium Meeting
March 26-27, 2020
Bethesda North Marriott Hotel & Conference Center
Cancelled
Virtual Meetings
“SCLC_CellMiner: Integrated genomics and therapeutics predictors of SCLC cell lines”
Yves Pommier, MD PhD
Chief, Developmental Therapeutics Branch
Head, Molecular Pharmacology Group
National Cancer Institute, National Institutes of Health
“Association of gene expression of 72 epigenetic molecular factors with DNA methylation and chemosensitivity in SCLC cell lines”
Julia Krushkal, PhD
Computational Biologist, Biometric Research Program
Computational & Systems Biology Branch
National Cancer Institute
“Acquired resistance to olaparib-temozolomide in SCLC PDX”
Marcello Stanzione, PhD
Postdoctoral Fellow, Dyson laboratory
Center for Cancer Research
Massachusetts General Hospital
“Defining putative tumor suppressors of SCLC development”
Kwon Park, PhD
Associate Professor
Microbiology, Immunology, and Cancer Biology
University of Virginia School of Medicine
“Identification of RUNX1T1 as a potential epigenetic modifier in small cell lung cancer”
Tian He
Graduate Student, Dowlati Laboratory
Case Comprehensive Cancer Center
Case Western Reserve University
“Dissecting cross-resistance in SCLC”
Benjamin Drapkin, MD, PhD
Assistant Professor
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
“Multimodal approach to circulating RNA detection in SCLC”
Patrick Nana-Sinkham, MD
Chair, Division of Pulmonary Disease & Critical Care Medicine
Virginia Commonwealth University School of Medicine
James Lee, MD PhD
Professor, Chemical & Biomolecular Engineering
The Ohio State University
“Continuous luminescence modeling to quantify growth of adherent and suspension SCLC”
Clayton Wandishin
Graduate Student, Chemical and Physical Biology Department
Vanderbilt University Medical Center
“DDR/IO combos in the world of inter- and intra-tumoral heterogeneity”
Lauren Byers, MD
Associate Professor, Department of Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
MD Anderson Cancer Center
“Recent explorations in small-land”
Charlie Rudin, MD PhD
Chief, Thoracic Oncology Service
Director, Druckenmiller Lung Center
Memorial Sloan Kettering Cancer Center
“Molecular characterization of neuroendocrine transformation in lung cancer”
Triparna Sen, PhD
Assistant Attending, Thoracic Oncology
Co-Director, Charles Rudin Lab, Molecular Pharmacology Program
Memorial Sloan Kettering Cancer Center
“Targeting delta-like ligand 3 for 177Lu-based radioimmunotherapy of SCLC”
J.T. Poirier, PhD
Assistant Professor, Department of Medicine
Director, Preclinical Therapeutics Program
Perlmutter Cancer Center, NYU Langone Health
“Diversity of pulmonary NE signals and targets revealed by scRNASeq”
Christin Kuo, MD
Assistant Professor, Department of Pediatrics
Stanford University School of Medicine
“Modeling the response of SCLC to radiation therapy”
Julien Sage, PhD
Professor, Department of Pediatrics and Genetics
Stanford University School of Medicine
“Skp2 E3 ubiquitin ligase: a downstream target in RB1-deficient SCLC”
Edward Schwartz, PhD
Professor, Department of Medicine (Oncology)
Professor, Department of Molecular Pharmacology
Albert Einstein College of Medicine
“A ubiquitin E3 ligase mediates resistance to PARP inhibitors in SCLC”
Benjamin Lok, MD
Assistant Professor, Department of Radiation Oncology
Medical Biophysics, Institute of Medical Science
Princess Margaret Cancer Centre, University of Toronto
“Genomic and transcriptomic features of relapsed SCLC”
Siddhartha Devarakonda, MD
Assistant Professor of Medicine
Siteman Cancer Center
Washington University School of Medicine
“Molecular comparison of PDX/CDX models with primary specimens”
Luc Girard, PhD
Assistant Professor, Hamon Center for Therapeutic Oncology Research
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
“Deep proteomic profiling of SCLC cell lines reveals a MYC-centric neuroendocrine signature”
Ehsan Irajizad, PhD
Biomathematics and Biostatistics
MD Anderson Cancer Center
“MYC-driven polyamine signature with a protein panel for early detection”
Johannes Fahrmann, PhD
Instructor, Clinical Cancer Prevention
MD Anderson Cancer Center
“Skp2 E3 ubiquitin ligase: a downstream target in RB1-deficient SCLC”
Edward Schwartz, PhD
Professor, Department of Medicine (Oncology)
Professor, Department of Molecular Pharmacology
Albert Einstein College of Medicine
“A ubiquitin E3 ligase mediates resistance to PARP inhibitors in SCLC”
Benjamin Lok, MD
Assistant Professor, Department of Radiation Oncology
Medical Biophysics, Institute of Medical Science
Princess Margaret Cancer Centre, University of Toronto
“Functional screens and mouse models identify MAX as a tumor suppressor in SCLC”
Arnaud Augert, PhD
Postdoctoral Fellow (MacPherson Lab)
Human Biology & Public Health Sciences Divisions
Fred Hutchinson Cancer Research Center
“Transcriptional programs and immune activation define four major subtypes of SCLC”
Carl Gay, MD PhD
Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
“MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate”
Trudy Oliver, PhD
Associate Professor, Oncological Sciences
Huntsman Cancer Institute, University of Utah
“The tuft cell variant of SCLC”
Chris Vakoc, MD PhD
Professor, CSHL Cancer Center
Cold Spring Harbor Laboratory
“Plasticity of MHC class I expression and immune rejection”
David Barbie, MD
Associate Director, Belfer Center for Applied Cancer Research
Associate Professor, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
“CDK7 inhibition potentiates genome instability triggering anti-tumor immunity”
Hua Zhang, PhD
Postdoctoral Fellow, Wong Laboratory
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
“A new ASCL1+ subtype, A2, forms a plastic, transit-amplifying compartment of SCLC tumors”
Sarah Groves
Graduate Student, Quaranta Laboratory
Quantitative and Chemical Biology Program
Vanderbilt University School of Medicine
“Computational Modeling of Subtype Interactions in SCLC to Modulate Tumor Composition”
Leonard Harris, PhD
Department of Biochemistry
Vanderbilt University School of Medicine
“Epigenome-wide DNA methylation analysis of SCLC cell lines suggests potential chemotherapy targets”
Julia Krushkal, PhD
Biometric Research Program
Computational & Systems Biology Branch
National Cancer Institute
“On the origins of SCLC”
Harold Varmus, MD
Lewis Thomas University Professor
Meyer Cancer Center, Weill Cornell Medicine
“Histologic transformation in lung cancer through basal cell intermediates”
Eric Gardner, PharmD, PhD
Postdoctoral Fellow, Varmus Lab
Meyer Cancer Center, Weill Cornell Medicine
“scRNASeq reveals intratumoral heterogeneity in therapy resistance”
Allison Stewart, PhD
Research Scientist, Byers Laboratory
MD Anderson Cancer Center
“Novel Chemotherapy-stable subpopulations are conserved across multiple PDX models”
Jonathan Lehman MD, PhD
Instructor in Medicine, Division of Hematology/Oncology
Vanderbilt University Medical Center
2019
Annual Meeting
IASLC 2019 Small Cell Lung Cancer Meeting
April 3-5, 2019
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Program Agenda
Virtual Meetings
“Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung cancer”
Ramaswamy Govindan, MD
Anheuser Busch Endowed Chair in Medical Oncology
Professor of Medicine, Division of Oncology
Director, Section of Medical Oncology
Washington University School of Medicine, Siteman Cancer Center
Obi Griffith, PhD
Assistant Professor of Medicine, Division of Oncology
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine, Siteman Cancer Center
Trudy Oliver, PhD
Associate Professor, Department of Oncological Sciences
Cell Response and Regulation Cancer Center Program
Huntsman Cancer Institute, University of Utah
“Using patient-derived models to understand drug responses in SCLC”
Anna Farago, MD PhD
Assistant Professor, Medicine, Harvard Medical School
Assistant, Medicine, Massachusetts General Hospital
Dana Farber/Harvard Cancer Institute
Benjamin Drapkin, MD, PhD
Instructor, Medicine, Massachusetts General Hospital
Nicholas Dyson, PhD
Professor of Medicine, Mary B. Saltonstall Chair in Oncology, Harvard Medical School
Geneticist, Center for Cancer Research
James and Shirley Curvey MGH Research Scholar
Scientific Director, Mass General Cancer Center
“Integrated Protometabolic Analysis Reveals Metabolic Vulnerabilities in SCLC”
Eric Haura, MD
Director, Lung Comprehensive Research Center
Co-Program Leader, Chemical Biology and Molecular Medicine Program
Department of Thoracic Oncology
H. Lee Moffitt Cancer Center & Research Institute
“Discovering tumor vulnerabilities linked to de-differentiation: Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies”
Thomas Graeber, PhD
Director, UCLA Metabolomic Center
Professor, Molecular & Medical Pharmacology
Member, Crump Institute for Molecular Imaging at UCLA
UCLA Molecular Biology Institute
“Phenotype interactions in SCLC development and detection”
Christine Lovly, MD, PhD
Co-Leader, Translational Research and Interventional Oncology Research Program
Associate Professor of Medicine (Hematology/Oncology)
Vanderbilt Ingram Cancer Center
Alissa Weaver, MD, PhD
Professor, Cell and Developmental Biology & Pathology
Microbiology, and Immunology
VU Center for Cancer Systems Biology
Vanderbilt Ingram Cancer Center
“Developing ASCL1 and NEUROD1 lineage oncogene targeted therapy for small cell lung cancer”
John Minna, MD
Director, Hamon Center for Therapeutic Oncology Research
The Moncrief Center for Cancer Genetics,
Co-Director of the Experimental Therapeutics Program, Simmons Cancer Center
Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology
Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Jane Johnson, PhD
Professor and Vice Chair, Department of Neuroscience
Shirley and William S. McIntyre Distinguished Chair in Neuroscience
UT Southwestern Medical Center
“Targeting BCAT1 and branched-chain amino acid metabolism for the detection and prevention of SCLC”
Kwon-Sik Park, PhD
Associate Professor, Microbiology, Immunology, and Cancer Biology
University of Virginia, School of Medicine
“RB1 WT SCLC and RB1 WT, KEAP1 WT, STK11 WT neuroendocrine negative LCNEC”
Dmitriy Sonkin, PhD
Computational Biologist, Computational & Systems Biology Branch
Division of Cancer Treatment & Diagnosis (DCTD)
National Cancer Institute
2018
Annual Meeting
Small Cell Lung Cancer Consortium Meeting
March 15-16, 2018
NCI Shady Grove, Rockville, MD
Program Agenda
Virtual Meetings
“Tissue Microarray (TMA) Project”
Afshin Dowlati, MD
Professor, Department of Medicine Division of Hematology and Oncology, School of Medicine
Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center
Case Western Reserve University
Gary Wildey, PhD
Program Manager
Case Comprehensive Cancer Center
Case Western Reserve University
“RB1 Loss Drives Prostate Cancer Lineage Plasticity and Therapeutic Resistance”
Leigh Ellis, PhD
Assistant Professor, Pathology, Harvard Medical School
Assistant Professor of Pathology, Oncologic Pathology
Dana-Farber Cancer Institute, Harvard Cancer Center
“Center for Systems Biology of Small Cell Lung Cancer”
Vito Quaranta, MD
Department of Biochemistry, Professor in Biochemistry & Pharmacology
Director of Quantitative Systems Biology Center
Co-Director of The Center for Matrix Biology
Vanderbilt University
“Understanding Different Subsets of Small Cell Lung Cancer”
David MacPherson, PhD
Associate Member, Human Biology Division
Associate Member, Public Health Sciences Division
Fred Hutchinson Cancer Research Center
“Enhancing Small Cell Lung Cancer Therapy with Pharmacological Ascorbate”
Bryan Allen, MD
Associate Professor of Radiation Oncology
Carver College of Medicine
University of Iowa Health Care
“A Tuft Cell Variant of Small Cell Lung Cancer”
Chris Vakoc, MD, PhD
CSHL Cancer Center
Gene Regulation and Cell Proliferation
Cold Springs Harbor Laboratory
2017
Annual Meeting
IASLC 2017 Small Cell Lung Cancer Meeting
March 15-17, 2017
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Program Agenda